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Although  considerable progress has been  achieved in  the  study of the  co- 
agulation of plasma by staphylocoagulase,  the precise identity of the  coagu- 
lase-reacting factor  (CRF)  has  remained  in  doubt.  The  claims linking  CRF 
with  various  factors  involved  in  the  dotting  of  blood  have  been  recently 
summarized  elsewhere  (1).  Questions  pertaining  to  the  possible  relation  of 
CRF  to  prothrombin  have  remained  particularly  challenging.  To  be  sure, 
prothrombin  and  CRF  activities  have  been  dissociated  by  repeated  Seitz 
(asbestos)  filtration  (2-4).  While  this observation establishes that  CRF may 
exist  independently  of  prothrombin  activity,  it  does  not  preclude  the  pos- 
sibility  that  other  factors  eliminated  by  the  filtration  procedure,  including 
prothrombin itself, may function similarly. The prime objective of the present 
report has therefore been twofold: 
1.  To purify and characterize CRF as recovered from human plasma after 
prothrombin  activity has been  reduced  to  a  minimum by serial  Seitz filtra- 
tion. 
2.  To  study  directly  the  CRF  activity  of  highly  purified  preparations  of 
human prothrombin. 
Materials and Methods 
Staphylocoagulase.--Highly purified products were used, to the extent that on analytical 
nitraeentrifugation, over 95 per cent of the material formed a single symmetrical peak. The 
method of purification has been described elsewhere (5). The concentration of the coagulase 
was adjusted so that it clotted an equal volume of non-inhibitory citrated human plasma within 
17 to 20 seconds. 
Prothrombin.--Four purified human  prothrombin  preparations  were furnished by  Dr. 
Walter H. Seegers. Several of these lots were prepared from 20 liter plasma pools of citrated 
blood bank discards, shipped in the frozen state from Atlanta to Detroit. The techniques of 
purification are referred to in recent studies by Seegers  and his associates (6). According to the 
data of Seegers, the potency of these products had such values as 24,400 units/mg, of tyrosine 
for lot 541216 and 20,700 units for lot 550503. 
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Plasma.--Outdated or  VDRL-positive citrated  human  blood  bank  discards were used, 
excluding those showing significant inhibition of clotting by coagulase when compared to a 
non-inhibitory plasma control. 
Filtration of Flasma.--Pools of  1 liter were filtered through  5  sterilizing Seitz asbestos 
pads, 14 cm. in diameter, collecting the filtrates in suction flasks under a vacuum. Unusually 
turbid plasmas were first passed through a  Seitz clarifying pad.  Before use,  all filters were 
thoroughly washed until the oxalate test for calcium ions turned negative. 
Titration of CRF.--The appropriate plasma or CRF preparations were diluted in physio- 
logical saline containing 2 mg./ml, of bovine albumin (Armour). To each dilution of CRF in a 
volume of 0.2 ml., 0.2 ml. of bovine fibrinogen (Armour fraction I) was added, at a concentra- 
tion of 250 rag. per cent. 0.2 ml. of coagulase was then blown into the tube as the stop watch 
was started.  The end point was taken  as the first wisp of fibrin or the first appearance of 
floccules with more slowly reacting mixtures. Observations were made at room temperature 
with a  loop magnifying 5 times, using a  fluorescent light source.  The clotting times of the 
various dilutions were plotted, and the per cent activity extrapolated arithmetically. Controls 
included the clotting times of mixtures of coagulase and fibrinogen as well as of plasma dilutions 
and  fibrinogen. 
Prothrornbin Time.--Minor modifications of the one step method of Ware and Stragnell (7) 
were adopted. For the prothrombin conversion, either thromboplastin (Difco,  Detroit)  and 
calcium, or simplastin (Warner-Chilcott, New York) with bovine serum as the source of accel- 
erator globulin, were employed. 
Nitrogen Detcrminations.--The micro-Kjeldahl technique was used as described by Kabat 
and Mayer (8), substituting for the indicator a mixture of methyl red and brom-cresol green. 
Paper Eleclrophoresis.--The determinations were made in a Spinco Model R  Durrum type 
apparatus  using veronal buffer at a  pH of 8.6,  ionic strength  of 0.075,  and  the runs were 
generally made at 5 ma. for 16 hours, as is customary for the electrophoresis of serum. 
Ultracentrifugation.--The preparations were sedimented in a Spinco analytical ultracentri- 
fuge at 59,780 a.P.M., or 259,700 g. Photographs were taken at 16 minute intervals, and runs 
generally were terminated within 2 hours. The lack of sufficient  material limited the observa- 
tions  to  obtaining  uncorrected  sedimentation  rates  only,  and  the  molecular weights were 
approximated from the charts of Svedberg and Pedersen (9), and Lundgren and Ward (10). 
Preparation of Absorption Columns.--Chromatographic apparatus  of varying dimensions, 
supplied  by Scientific Glass Co., was employed.  For processing 2  liter batches  of plasma, 
columns were used which were 660 mm. in length, 80 mm. in diameter, and had a joint size of 
71/40. 500 gin. of hyflo grade of celite (johns-Manville, New York) and 110 ml. of aluminum 
hydroxide  gel  (amphogel,  without  flavor, Wyeth and  Co.,  Philadelphia)  were  thoroughly 
mixed with 3 liters of distilled water, the mixture was introduced into the column, and packed 
solidly by tapping gently with a flanged glass rod as the water was collected in a suction flask 
under negative pressure maintained by an oil vacuum pump. The column was further washed 
by passing through it several liters of distilled water. The plasma at 6-8°C. was then carefully 
layered on the column to minimize any disturbance of the surface, and only columns were 
processed further which permitted an even progression of the plasma front and which lacked 
any significant faults or cracks. All fractions were collected under negative pressure in suction 
flasks at a room temperature of about 21.5°C.,  and tested for activity. 
RESULTS 
The purification  of  CRF.--Munro  and  Munro  (11)  have  used  phosphate 
buffer  elution  from  amphogel  in  the  purification  of  prothrombin,  and  pre- 
liminary  studies  have  indicated  that  this  aluminum  hydroxide  preparation MORRIS  TACER  677 
may also  be  useful in  the purification of  CRF  (12).  Working with plasma 
lots of  100  ml.,  purification of  the order of  125-fold  was  attained, but  the 
products proved quite labile, and at times significantly active as prothrombin 
as well. It became necessary to modify the procedure  so  that larger lots of 
plasma could be processed which might make feasible higher concentrations 
thus favoring its stability. 
After various grades of celite were tested, hyflo proved most acceptable as the filler,  and 
different amounts of filler and amphogel were first tested in smaller lots. The ratio of 500 gin. 
of hyflo to 110 ml. of amphogel was adopted for the processing of 2 liter batches of plasma. 
The scheme of purification of CRF on celite-amphogel columns is herewith summarized. 
t.  Filter 2 liters of plasma through five successive washed sterilizing Seitz pads, using 1 
liter of plasma per pad 14 cm. in diameter. 
2. Layer carefully the plasma on the column prepared as described under Materials and 
Methods. 
3. Discard the plasma eluate. 
4. Add 2 liters of 0.1 ~  phosphate buffer at a pH of 8. Discard eluate. 
5. Add 1 liter of 0.2 ~ phosphate buffer at a pH of 8. Discard eluate. 
6. Add 1 to 2 liters of 0.2 ~t phosphate buffer at a  pH of 8.6 and collect fractionally the 
eluates, adjust pH to 7.0, and check each sample separately for CRF activity. Select the most 
purified and active sample for further processing. 
The course of a  representative column purification of CRF is summarized 
in Tables I a  and I b, the former presenting the clotting times obtained, and 
the latter expressing the results in terms of yield and purification. The 5  X 
Seitzed plasma is taken as the base line (sample 1), and itself involves a  loss 
of some 50 per cent of CRF and over 95 per cent loss of prothrombin of the 
unfiltered plasma.  The  greatest  removal  of  inactive  nitrogenous impurities 
takes place in samples 2 and 3,  with only approximately 15  per cent of the 
CRF sacrificed. The use of 0.2 M phosphate buffer at pH 8 serves essentially 
as a  washing step,  with little further release  of nitrogen or activity. Upon 
the introduction of 0.2 ~r phosphate buffer at a pH of 8.6, however, significant 
CRF activity is released. While all three fractions tested separately showed 
CRF activity, the  second lot  (5 b)  possessed  the greatest activity, and  the 
highest purification factor of 173-fold.  There was, however, a  slight concen- 
tration of prothrombin activity as well, estimated at about 10 per cent of the 
prothrombin content of the original unfiltered plasma. 
In the course of carrying out column purifications on 20  different plasma 
pools,  it became evident that many inherent and technical factors may in- 
fluence the results significantly. For example, raising the amount of ampho- 
gel to 130 ml. led to a  great delay in the elution of active CRF with 0.2 
buffer at a pH of 8.6; indeed, not until 900 ml. of buffer was used did a  sub- 
sequent  sample  exhibit a  high order  of purification of some  210-fold.  It  is 
quite probable that with the aid of constant positive pressures and an auto- 
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Attention has  already been  drawn  to  the  need  of cardully packing  the  col- 
umn,  and to the fact that  the development of cracks and an uneven  plasma 
advance may lead to unpredictable results. The outcome has also been preju- 
diced by some  operations  taking  considerably longer than  the  5  to  6  hours 
TABLE I a 
Puri.fu:ation of CRF on Hyflo-Amphogel  Column 
1 
2 
3 
4 
5a 
5b 
5c 
Sample 
5 X  Seitzed plasma 
Plasma eluate 
0.1 M phosphate pH 8.0 
0.2 M phosphate pH 8.0 
0.2 M phosphate pH 8.6 
0.2 ~ phosphate pH 8.6 
0.2 M phosphate pH 8.6 
CRF dotting times at final plasma 
dilutions below 
1:30  I  1:60  1:120 
--.--t 
$$C.  $$C.  $$C. 
335 
205  350 
>420 
42  76  157 
32  50  74 
65  135 
1:240  1:480 
S~¢..  eec. 
195  305 
Pro- 
thrombin* 
times 
79 
90 
75 
85 
85 
60 
87 
* 100 per cent prothrombin, 28 seconds; 50 per cent prothrombin, 35 seconds; 25 per cent 
prothrombin, 45 seconds; 10 per cent prothrombin, 55 seconds;  1 per cent prothrombin, 85 
seconds. 
TABLE I b 
Purification  of CRF on Hyflo-Amphogel  Column 
1 
2 
3 
4 
5a 
5b 
5c 
Sample 
5 X  Seitzed plasma 
Plasma eluate 
0.1 •  phosphate pH 8 eluate 
0.2 M phosphate pH 8 eluate 
0.2 M  phosphate pH 8.6 eluate 
0.2 ~ phosphate pH 8.6 eluate 
0.2 M  phosphate pH 8.6 eluate 
Volume 
ml. 
2000 
2~0 
2~0 
1200 
350 
380 
380 
CRF 
psr  C~n[ 
100 
5 
10 
<3 
50 
100 
35 
Total CRF 
units 
(volume X 
per cent 
CRF) 
200,000 
10,000 
20,000 
3,600 
17,500 
38,000 
13,000 
CRF 
yldd 
100 
5 
10 
1.8 
8.75 
19.0 
6.5 
N/ml. 
8.65 
7.96 
4.05 
0.06 
0.14 
0.05 
0.03 
CRF 
per 
mg.N 
11.5 
0.6 
2 
50 
357 
2000 
1166 
Purifi- 
cation 
factor 
31 
173 
101 
generally sufficient to process 2 liters. This delay was at first attributed to an 
excessively tight packing of the columns, but actually was traced to the plug- 
ging of the flitted disk of the inner member of the chromatographic assembly. 
This  difficulty may  be  best overcome by thoroughly  cleansing the  disks be- 
fore each use, or by employing perforated disks protected by glass wool. 
Since  the  best  products  attained  by  the  column  porcedure  had  nitrogen Mol~ms XAG~-R  679 
values in the range of 0.03  to 0.06 mg. per ml. they were too dilute for direct 
further study on paper electrophoresis and on analytical ultracentrifugation. 
These fractions also proved to be quite labile on standing, even when refrig- 
erated. Various techniques were, therefore, explored to concentrate the prod- 
uct, and to attain further purification. Prolonged rotation dialysis against 25 
per  cent dextran in the cold bath at 0°C.  achieved excellent concentration, 
with little loss of activity, and the removal of some cold precipitable impuri- 
ties. Such concentrated products were then further purified by the fractional 
addition of ammonium sulfate. Subsequently, it was found feasible to treat 
the CRF directly with ammonium sulfate at 0°C., provided the final column 
eluates were processed at once.  Substantial impurities were first cut off by 
adding ammonium sulfate crystals to 33 per cent saturation, and allowing the 
precipitate  to  form in  the  cold for about  6  hours.  This  fraction contained 
fibrinogen, and relatively little CRF. The final product was generally precipi- 
tated by adding ammonium sulfate to a  final concentration of 45  to 50 per 
cent. The precipitates which formed in the cold then redissolved readily in a 
small volume of saline, and formed the final active product. However,  this 
step  often involved a  considerable loss  of  CRF.  Such  procedures  generally 
resulted in an additional purification factor of some 40- to 50-fold relative to 
the initial filtered plasma. Thus, in the case of sample 5b of Table I a and I b 
the ammonium sulfate treatment raised the purification factor from 172-fold 
to 210-fold,  and concentrated the sample 16-fold.  A 40 per cent loss of CRF 
yield, however, was incurred.  These products were now sufficiently concen- 
trated and purified to render possible direct studies by paper electrophoresis 
and by analytical ultracentrlfugation to serve as a  basis of comparison with 
purified human prothrombin. 
Paper Electrophoresis of Purified CRF.--On paper electrophoresis, the puri- 
fied CRF preparations invariably stained the area between the beta and the 
gamma globulin zones when tested under the conditions applied to the sepa- 
ration of serum proteins. This finding is expressed graphically in Fig. 1, and 
represents  the  tracing  of  the  CRF  superimposed  on  the  tracing  of  human 
serum,  as  recorded  by  the  Spinco  calibrated  recording photometer  (analy- 
trol). To determine the relation of CRF activity to the protein-stained zone, 
duplicate strips were left unstained, and on the completion of the migration, 
were dried and sectioned at I cm. intervals. These strips were then eluted with 
a  constant volume of phosphate buffer, and the CRF activity was found to 
correspond to the zone of maximal staining between the beta and the gamma 
globulins. 
Analytical Ultracentrifugation of Purified CRF.--Although subject to some 
variation depending on concentration, all samples exhibited a major symmet- 
rical peak which in three separate lots gave uncorrected sedimentation rates 
of 2.75,  2.99,  and 3.07  respectively. In addition, a  heavier and much smaller 680  COAGULASE-REACTING ]~ACTOR AND PROTHROMBIN 
component was found,  with  sedimentation  rates  of 6.37,  6.68,  and  6.95  re- 
spectively. It may thus be estimated that the major component has a molecu- 
lar  weight approximating  30,000,  while  the minor  component approximates 
molecular weights between 110,000 and 160,000.  (Fig.  3). 
Comparison between Human Prothrombin and Purified CRF 
Previous tests of purified  bovine prothrombin  of Seegers (2) failed to indi- 
cate any significant  reactivity with  staphylocoagulase.  Since  bovine plasma 
is deficient in CRF, the non-reactivity of the bovine preparations may repre- 
sent a  species effect,  and  need not apply to human  or rabbit prothrombin, 
derived from plasmas high  in CRF content. Direct studies of highly purified 
d 
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PROTHROMBIN  FACTOR 
FIG. 1. Paper electrophoresis  of purified CRF and of purified Seegers human prothrombin, 
superimposed on human serum, photometer  (analytrol) representation. A,  albumin peak; 
ax, ot~, ~, and "y are the respective globulin peaks. 
and active human prothrombin were therefore undertaken  to furnish a  basis 
for comparison with the purified CRF. 
The four human prothrombin preparations of Seegers proved to be highly 
reactive with coagulase.  In Fig. 2,  the effect of coagulase  on prothrombin  is 
compared to the conversion  of prothrombin by means of thromboplastin,  cal- 
cium,  and accelerator globulin  in the form of bovine serum. At this level of 
coagulase  potency, the coagulation proceeded as rapidly upon the addition of 
coagulase  as upon  the addition  of the battery of accelerators and  cofactors 
implicated in the physiological  conversion  of prothrombin to thrombin. 
Although  purified  prothrombin  was  highly  reactive  with  coagulase,  its 
characteristics on paper electrophoresis differed sharply from those established 
by the purified CRF (Fig.  1). The prothrombin peak fell between the alpha2 
and  the beta serum peaks when 0.01 ml.  of a  2 per cent solution was used. 3/[ORRIS  TAGER  681 
When the amount was doubled,  the prothrombin peak tended  to overlap the 
alpha2 position; indeed with one preparation it was shifted  more towards the 
alpha1 position.  In no instance,  however, did any of the purified  human pro- 
thrombin preparations localize in  the zone between the beta and the gamma 
position  in  which  the  purified  CRF  consistently  fell.  Buffer  elution  of  un- 
stained  strips  again  indicated  a  close  correspondence  between  activity  and 
the zones corresponding  to  the  maximal protein  staining. 
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Fro. 2. The action of coagulase on purified human prothrombin of Seegers  compared to the 
"physiological" conversion of prothrombin. 
Controls: prothrombin 1:100 q- fibrinogen, 480 seconds; prothrombin 1:200 --I-  fibrinogen, 
900 seconds; prothrombin 1:100 -I- fibrinogen q- thromboplastin  -t- calcium, 142 seconds; 
prothrombin 1  : 100 -k ac. glob. q- fibrinogen, 480 seconds; ac. glob. -t- fibrinogen -[- thrombo- 
plastin q- calcium, 142 seconds; coagulase -b fibrinogen, 15 minutes. 
On  analytical  ultracentrifugation,  the  human  prothrombin  preparations 
examined did not possess the homogeneity and consistency reported by Lamy 
and  Waugh  (13)  for  purified  bovine  prothrombin  preparations  of  Seegers. 
These  authors  reported  a  sedimentation  constant  of  4.85,  and  a  molecular 
weight  of 62,700.  This finding  was at variance  with  an estimated  molecular 
weight  of  140,000  found  with  other  preparations  and  referred  to  by Seegers 
and Ware  (14).  In the present study,  the major human prothrombin compo- 
nent  gave uncorrected  sedimentation  rates  of  such  values  as  6.2  and  6.38, 
corresponding closely to the higher molecular weight range reported for bovine 
prothrombin,  while  a  minor  component fell in  the  range  reported  by Lamy 
and  Waugh.  Regardless  of  the  question  of  the  purity  of  these  preparations 682  COAGULASE-REACTING  FACTOR  AND  PROTHROMBIN 
versus  the possibility of complexing of the prothrombin molecule, none of the 
values corresponded  to  those of  the  principal  CRF  component.  (Fig. 3). 
CRF Activity of Prothrombin Derivatives 
The observation that CRF activity is associated with plasma products very 
low in prothrombin  (purified  CRF)  as well as with highly purified prothrom- 
bin itself, raises the question  of the possible relation of these preparations  to 
each  other.  It  becomes  pertinent  to  determine  whether  the  prothrombin 
molecule  might  be  deliberately  altered  to  cause  it  to  lose  its  prothrombin 
Fro. 3. Ultracentrifugal patterns  of purified CRF and human prothrornbin. Top picture: 
Purified CRF in saline (separation cell), s  =  2.99 (large peak) 6.68 (small peak). Bottom 
picture:  Purified human prothrombin, 1 per cent, in saline (standard  analytical cell); s  = 
6.20 (large peak) and 4.93 (small peak). 
function,  and yet not abolish its function as CRF. It has already been estab- 
lished  (2)  that  the  conversion  of  prothrombin  to  thrombin,  involving  the 
breakdown of prothrombin into many smaller units,  does not  eliminate CRF 
activity. When  the  thrombin is sufficiently diluted  so that  its direct  reaction 
with  fibrinogen does not  obscure the effect of coagulase,  it  is still  possible to 
demonstrate  a  very significant  acceleration  of  clotting  upon  the  addition  of 
the staphylococcal product. 
Further  support  for  the  concept  that  prothrombin  activity  per  se  is  not 
essential  for  the  exhibition  of  CRF  activity  was  recently  furnished  by  the 
study  of  a  preparation  of  "autoprothrombin,"  prepared  as  follows  by  Dr. 
Takeshi Abe in Dr. Seegers' laboratory (15).  Prothrombin was first incubated 
with platelet factor 3 and  calcium, followed by the addition of purified accel- 
erator globulin. The product was then ultracentrifuged  to remove the platelet 
factor, and  the material shell frozen and  stored in  the deep freeze overnight. MORRIS  TAGER  683 
After  thawing,  the  material  was  dialyzed against  cold distilled  water,  and 
lyophilized. This procedure caused a drop of prothrombin activity from 25,800 
units per ml. to one of 256 units per ml., and the thrombin activity remained 
very small.  When  this  preparation  was reacted with  coagulase however,  it 
showed excellent CRF content, although the speed of clotting at higher dilu- 
tions was slower than  with  the unmodified prothrombin  from which it has 
been derived (Table II). 
TABLE II 
CRF Clotting Times of Purified Prothrombin and Its "Autoprothrombin" 
Prothrombin dilution  of  "Autoprothrombin" dilution of 
1:2400  1:300  1:600 
26  30 
1:1200  1:2400  1:4800  1:300  1:600  1:1200 
Se~.  $8C.  $~C.  $6C.  $¢C,  SeG. 
36  50  91  26  32  61 
$~. 
132 
Prothrombin 1:300 plus fibrinogen and no coagulase: no clot in 30 minutes; 
"Autoprothrombin" 1:300 plus fibrinogen and no coagulase: clot in 100 seconds; 
Coagulase plus fibrinogen control: clot in 25 minutes. 
DISCUSSION 
The identity of CRF has been in question since this factor was first pro- 
posed by Smith and Hale (16). In the opinion of many observers (1-4, 16, 17), 
the key to the problem has been the relation of CRF to prothrombin.  Other 
principal contenders, such as fibrinogen,  have been essentially eliminated from 
consideration.  The arguments  for and against  relating  CRF to prothrombin 
have been recently summarized  (1). The present study has sought to resolve 
an apparent inconsistency: the view that prothrombin and CRF are identical, 
and the separation of prothrombin and CRF activity by repeated Seitz filtra- 
tion. 
By direct test, it has been established that 4 separate highly purified and 
active  human  prothrombin  preparations  of  Seegers  effectively function  as 
CRF.  When,  however,  prothrombin  activity  is  virtually  eliminated,  as  by 
converting prothrombin to autoprothrombin or to thrombin,  CRF activity is 
not likewise eliminated. Evidently, therefore, the whole prothrombin molecule 
is not essential for CRF function. 
The purification of CRF after Seitz filtration herewith reported lends fur- 
ther support  to the existence of CRF independent  of prothrombin  activity. 
Duthie  and  Lorenz  (17)  made  the  intriguing  suggestion  that  the  filtration 
procedure does not actually remove prothrombin,  but so alters it that  it no 
longer functions as prothrombin, but yet operates as CRF. The present data, 
however, have indicated  that  the purified  CRF recovered has a  distinctive 684  COAGULASE-REACTING FACTOR AND PROTHROMBIN 
mobility on  paper  electrophoresis,  and  that  its principal  component has  a 
sedimentation rate differing from that of any of the prothrombin components. 
It is tempting to speculate that  CRF is a part of the prothrombin molecule, 
with a molecular weight estimated to be about half that of the minor human 
prothrombin molecule,  and  half that  of the single  bovine prothrombin  com- 
ponent reported by Lamy and Waugh (13). However, there is no direct proof 
that  this  CRF is derived from prothrombin,  nor is  there  certain knowledge 
that  this fraction exists in native plasma or is split off during  the filtration 
procedure. 
Both  the purified  CRF and  the purified human  prothrombin  presented a 
major and a  minor component on ultracentrifugation.  It is possible that  the 
heavier components represent an aggregation of smaller units, or polymeriza- 
tion,  rather  than unrelated impurities.  While it is noteworthy that  the com- 
ponents fit into a pattern of multiples of molecular weights of approximately 
35,000, similar relations have been earlier claimed for many unrelated proteins 
as well (18). It is, therefore, not possible at the present time to appraise with 
any degree of assurance the significance  of the minor peaks observed. Direct 
evidence for the association of activity and the maximal protein concentration 
has  been obtained,  however,  by buffer elution of paper strips  after electro- 
phoresis,  both with prothrombin and with CRF. 
The present observations therefore lend themselves to a  unifying hypothe- 
sis of the nature of CRF. It is suggested that  the capacity to react with co- 
agulase, or CRF activity, resides in some groups of the prothrombin molecule, 
and these groups are not involved in prothrombin function as such. The whole 
molecule will exhibit both prothrombin and  CRF activity, but a  part of the 
molecule,  no longer functioning as prothrombin is implicated in CRF activity, 
and  is preserved in such derivatives of prothrombin  as thrombin and  auto- 
prothrombin,  and possibly the purified CRF of Seitz-filtered  plasma as here 
described. This hypothesis explains  why prothrombin and CRF activities may 
parallel  each other closely,  as  noted  following  dicumarol  (4, 19)  or phenyl- 
indanedione (19) administration,  or diverge partially or completely, as occurs 
after Seitz filtration. 
SD'~MARY 
The coagulase-reacting  factor  (CRF) of human plasma has been purified, 
concentrated, and largely  freed of prothrombin  activity  by Seitz  filtration, 
absorbtion on hyflo-amphogel columns, controlled  phosphate  buffer  elution, 
and fractional  ammonium sulfate  precipitation. 
The purified CRF preparations localized  between the beta and the gamma 
globulin position on paper electrophoresis,  and  the principal  of two compo- 
nents  observed  on  analytical  ultracentrifugation  gave  sedimentation  rates 
between 2.75 and 3.07. MORRIS  TAGER  685 
Highly purified prothrombin preparations of Seegers effectively react with 
staphylocoagulase to lead to the coagulation of plasma. 
The  electrophoretic  and  ultracentrifugal  properties  of  the  human  pro- 
thrombin preparations  examined differ significantly from those of the puri- 
fied CRF. 
Derivatives of prothrombin, involving a  loss of prothrombin activity, such 
as  thrombin  and  "autoprothrombin,"  do  not  correspondingly lose  in  CRF 
function. 
The hypothesis is proposed that  CRF activity is resident in some compo- 
nent or components of the prothrombin molecule not involved in prothrombin 
function per se, and that therefore prothrombin and CRF activity may either 
parallel each other when the molecule is intact or diverge when the smaller 
units only are involved. 
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